Press release
Parkinson's Disease Levodopa-Induced Dyskinesia (LID) Market New Product Development & Latest Trends
Parkinson's Disease Levodopa-Induced Dyskinesia (LID) Market
Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting movement, characterized by tremors, stiffness, and impaired coordination. Levodopa remains the gold standard for managing motor symptoms, but long-term use often results in levodopa-induced dyskinesia (LID) - a debilitating complication involving involuntary, erratic movements.
As patients live longer due to improved disease management, the incidence of LID continues to rise. The burden of dyskinesia not only reduces quality of life but also complicates therapeutic decision-making for clinicians. Advances in pharmacology, surgical interventions, and digital health monitoring are driving momentum in the LID treatment market. The growing focus on patient-centric solutions and innovative therapies is shaping a promising outlook through 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71914
Market Overview
The global Parkinson's disease levodopa-induced dyskinesia (LID) market was valued at USD 1.6 billion in 2024 and is projected to grow at a CAGR of 6.6% between 2024 and 2034, reaching approximately USD 3.0 billion by 2034.
Key Highlights
• Drivers: Rising prevalence of Parkinson's disease, growing use of levodopa, increasing demand for adjunctive therapies, and strong research pipelines.
• Challenges: High treatment costs, adverse effects of existing therapies, and limited awareness in low-income regions.
• Leading Players: Adamas Pharmaceuticals (Supernus Pharmaceuticals), Amneal Pharmaceuticals, Kyowa Kirin, AbbVie, Sunovion Pharmaceuticals, Teva Pharmaceutical Industries, UCB Pharma, Pfizer Inc., Novartis AG, and Medtronic plc.
Segmentation Analysis
By Product
• Pharmacological Therapies
o Amantadine Extended-Release Formulations
o Dopamine Agonists
o Anticholinergics
o Novel Adjunctive Agents (in clinical development)
• Surgical Interventions
o Deep Brain Stimulation (DBS)
o Ablative Procedures
• Non-Pharmacological Approaches
o Physiotherapy & Exercise Programs
o Digital & Cognitive Therapies
By Platform
• Prescription Medications
• Medical Devices (DBS Systems, Wearables)
• Digital Health Platforms
By Technology
• Extended-Release Drug Formulations
• Neuromodulation Devices
• Digital Monitoring Tools (AI-powered movement trackers, telehealth integration)
By End Use
• Hospitals
• Neurology Specialty Clinics
• Ambulatory Care Centers
• Homecare & Digital Platforms
By Application
• Early-Onset Parkinson's Patients Developing LID
• Late-Stage Parkinson's Patients with Advanced LID
Segmentation Summary
Pharmacological therapies - particularly extended-release amantadine formulations - dominate the LID market, offering the first FDA-approved treatment specifically targeting dyskinesia. Surgical options like deep brain stimulation (DBS) remain critical for advanced cases, while digital monitoring platforms are emerging as supportive tools for real-time symptom tracking.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71914/parkinson-s-disease-levodopa-induced-dyskinesia-market
Regional Analysis
North America
• Largest market share due to high diagnosis rates, advanced healthcare systems, and widespread adoption of novel therapies.
• The U.S. leads, with strong FDA approval pipelines and high uptake of amantadine extended-release.
Europe
• Robust demand supported by government-backed healthcare systems and strong adoption of DBS devices.
• Germany, the U.K., and France lead in clinical research and patient access to advanced therapies.
Asia-Pacific
• Fastest-growing region due to rising prevalence of PD, increasing life expectancy, and expanding healthcare infrastructure.
• Japan leads in adoption of advanced therapies, while China and India present opportunities for affordable treatment expansion.
Middle East & Africa
• Gradual improvements in neurological care and growing access to PD therapies.
• GCC countries show higher adoption of DBS and advanced pharmacological solutions.
Latin America
• Brazil and Mexico lead the region with expanding access to neurology specialists and novel treatments.
Regional Summary
North America and Europe dominate current revenues, but Asia-Pacific is expected to record the highest CAGR due to its large patient pool, healthcare modernization, and growing affordability of advanced treatments.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71914
Market Dynamics
Key Growth Drivers
• Rising prevalence of Parkinson's disease globally.
• Growing adoption of extended-release amantadine therapies.
• Increasing uptake of deep brain stimulation for advanced cases.
• Expansion of digital health platforms enabling better monitoring.
Key Challenges
• High treatment costs and reimbursement limitations.
• Limited availability of advanced therapies in emerging economies.
• Adverse effects of long-term pharmacological treatments.
Latest Trends
• Development of next-generation adjunctive agents for LID management.
• Growth in wearable and AI-based monitoring tools.
• Expansion of DBS applications with improved device precision.
• Increased patient participation in clinical trials due to advocacy group support.
Competitor Analysis
Major Players
• Adamas Pharmaceuticals (Supernus Pharmaceuticals) - Innovator in extended-release amantadine for LID.
• Amneal Pharmaceuticals - Expanding generics and specialty neurology portfolio.
• Kyowa Kirin - Active in neuropharmaceutical development.
• AbbVie - Focused on advanced Parkinson's therapies and neurology pipeline.
• Sunovion Pharmaceuticals - Specialist in CNS drug development.
• Teva Pharmaceutical Industries - Strong in generics and specialty PD treatments.
• UCB Pharma - Expanding footprint in neurology and movement disorders.
• Pfizer Inc. - Active in CNS research collaborations.
• Novartis AG - Involved in generics and neurology R&D.
• Medtronic plc - Global leader in deep brain stimulation devices.
Competitive Landscape Summary
The LID market is moderately consolidated, with specialized pharma companies leading pharmacological therapies and Medtronic dominating surgical interventions. Innovation in extended-release formulations, pipeline adjunctive therapies, and AI-powered monitoring tools is shaping competition.
Conclusion
The Parkinson's disease levodopa-induced dyskinesia market is set for significant growth, driven by rising PD prevalence, the introduction of targeted pharmacological solutions, and the expansion of surgical and digital interventions. While challenges such as high costs and limited access in emerging markets remain, innovation and global awareness campaigns are creating strong opportunities.
By 2034, the LID market is projected to reach USD 3.0 billion, underscoring its importance as a critical therapeutic area within neurology. Stakeholders who focus on combining drug innovation, device development, and digital health integration will be best positioned to capture growth.
For patients, this evolving landscape offers hope for improved quality of life and long-term management of one of Parkinson's most debilitating complications.
This report is also available in the following languages : Japanese (パーキンソン病レボドパ誘発性ジスキネジア市場), Korean (파킨슨병 레보도파 유발 디스키네시아 시장), Chinese (帕金森病左旋多巴诱发的运动障碍市场), French (Marché de la dyskinésie induite par la lévodopa dans la maladie de Parkinson), German (Markt für Levodopa-induzierte Dyskinesien bei Parkinson), and Italian (Mercato della discinesia indotta dalla levodopa nel morbo di Parkinson), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71914
Our More Reports:
Obesity Market
https://exactitudeconsultancy.com/reports/71968/obesity-market
Adrenal Crisis Market
https://exactitudeconsultancy.com/reports/71970/adrenal-crisis-market
Danon Disease Market
https://exactitudeconsultancy.com/reports/71972/danon-disease-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Levodopa-Induced Dyskinesia (LID) Market New Product Development & Latest Trends here
News-ID: 4179693 • Views: …
More Releases from Exactitude Consultancy
Parkinson's Disease Psychosis (PDP) Market reaching approximately USD 3.7 billio …
Parkinson's disease (PD) is a chronic neurodegenerative disorder marked by tremors, rigidity, and movement difficulties. Beyond motor symptoms, many patients also develop Parkinson's disease psychosis (PDP), a non-motor complication characterized by hallucinations and delusions. PDP affects nearly half of advanced PD patients, contributing significantly to morbidity, caregiver burden, and long-term care requirements.
Historically, PDP management has been challenging because many antipsychotics worsen motor symptoms by interfering with dopamine pathways. However, with…
Peripheral Nerve Injuries Market reaching approximately USD 4.9 billion by 2034
Peripheral nerve injuries (PNIs) occur when nerves outside the brain and spinal cord are damaged, often leading to loss of motor function, sensory deficits, or chronic neuropathic pain. These injuries are commonly caused by trauma, surgery, repetitive stress, or medical conditions such as diabetes. Depending on severity, PNIs may involve partial or complete disruption of nerve fibers, significantly affecting patient quality of life.
The burden of PNIs is rising globally due…
Post-Traumatic Stress Disorder (PTSD) Market reaching approximately USD 13.4 bil …
Post-traumatic stress disorder (PTSD) is a psychiatric condition that develops after exposure to traumatic events such as combat, natural disasters, serious accidents, or violence. It manifests through symptoms like flashbacks, nightmares, heightened anxiety, and emotional numbness, often impairing daily functioning and quality of life. While once underdiagnosed and stigmatized, PTSD is increasingly recognized as a major public health concern worldwide.
The growing prevalence of PTSD among military veterans, first responders, survivors…
Neuromyelitis Optica Market Detailed Industry Report Analysis 2025-2034
Introduction
Neuromyelitis optica (NMO), also known as Devic's disease, is a rare autoimmune disorder of the central nervous system characterized by severe inflammation of the optic nerves and spinal cord. Patients often experience vision loss, paralysis, sensory impairment, and bladder dysfunction. Once considered a variant of multiple sclerosis (MS), NMO is now recognized as a distinct condition, thanks to advancements in diagnostics such as aquaporin-4 (AQP4) antibody testing.
Though rare, NMO can…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
